Market closed
Rallybio/$RLYB
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Rallybio
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
Ticker
$RLYB
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
25
Website
Rallybio Metrics
BasicAdvanced
$41M
Market cap
-
P/E ratio
-$1.57
EPS
-1.67
Beta
-
Dividend rate
Price and volume
Market cap
$41M
Beta
-1.67
52-week high
$3.46
52-week low
$0.95
Average daily volume
83K
Financial strength
Current ratio
9.553
Quick ratio
9.176
Total debt to equity
0.325
Management effectiveness
Return on assets (TTM)
-39.29%
Return on equity (TTM)
-68.90%
Valuation
Price to revenue (TTM)
70.323
Price to book
0.58
Price to tangible book (TTM)
0.58
Price to free cash flow (TTM)
-0.823
Growth
Earnings per share change (TTM)
-12.52%
3-year earnings per share growth (CAGR)
-6.31%
What the Analysts think about Rallybio
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Rallybio stock.
Rallybio Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Rallybio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Rallybio News
AllArticlesVideos
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212
Business Wire·2 days ago
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting
Business Wire·2 months ago
Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Rallybio stock?
Rallybio (RLYB) has a market cap of $41M as of November 23, 2024.
What is the P/E ratio for Rallybio stock?
The price to earnings (P/E) ratio for Rallybio (RLYB) stock is 0 as of November 23, 2024.
Does Rallybio stock pay dividends?
No, Rallybio (RLYB) stock does not pay dividends to its shareholders as of November 23, 2024.
When is the next Rallybio dividend payment date?
Rallybio (RLYB) stock does not pay dividends to its shareholders.
What is the beta indicator for Rallybio?
Rallybio (RLYB) has a beta rating of -1.67. This means that it has an inverse relation to market volatility.